Alibaba vs AstraZeneca: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Alibaba and AstraZeneca side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

3. 1999Alibaba

   Alibaba.com Launched

   Jack Ma and 17 co-founders launch Alibaba.com from a Hangzhou apartment with $60,000 in pooled savings, creating a B2B online marketplace connecting Chinese manufacturers with international buyers.

4. 1999Alibaba

   First Major Investment from SoftBank

   Masayoshi Son invests $20 million in Alibaba in a meeting reportedly lasting five minutes, alongside $5 million from Goldman Sachs, providing survival capital through the imminent dot-com crash.

5. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

6. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

7. 2001Alibaba

   Gold Supplier Program Launch

   Alibaba launches the Gold Supplier verified membership program at $3,000 per year, generating approximately $10 million in first-year revenue and proving the B2B marketplace model's commercial viability.

8. 2003Alibaba

   Taobao Launches to Challenge eBay

   Alibaba secretly develops and launches Taobao, a consumer-to-consumer marketplace offered free to both buyers and sellers, directly targeting eBay's Chinese market position. Within three years, Taobao surpasses eBay's Chinese market share.

9. 2004Alibaba

   Alipay Escrow Service Created

   Alibaba creates Alipay as a payment escrow solution for Taobao transactions, holding buyer funds until delivery confirmation before releasing payment to sellers solving the trust barrier that was limiting online commerce adoption.

10. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

11. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

12. 2008Alibaba

    Tmall (Taobao Mall) Launch

    Alibaba launches a premium B2C marketplace initially called Taobao Mall (later rebranded Tmall), allowing established brands to operate official storefronts with higher trust credentials and enabling Alibaba to serve the premium consumer segment.

13. 2009Alibaba

    Alibaba Cloud Founded

    Alibaba launches Alibaba Cloud (Aliyun) as a cloud computing business, a decade ahead of many enterprise adoption cycles, positioning it to become Asia Pacific's dominant cloud provider.

14. 2011Alibaba

    First Singles' Day Shopping Festival

    Alibaba transforms the informal 'Singles' Day' celebration on November 11 into a promotional shopping event on Taobao and Tmall, generating ~$130 million (936 million yuan) in sales a figure that would grow more than 100-fold in subsequent years.

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2014Alibaba

    Record-Breaking NYSE IPO

    Alibaba completes its initial public offering on the New York Stock Exchange on September 19, 2014, raising $25 billion the largest IPO in US stock market history at that time at a valuation of approximately $168 billion.

17. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

18. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

19. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

20. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

21. 2019Alibaba

    Dual Listing on Hong Kong Stock Exchange

    Alibaba completes a secondary listing on the Hong Kong Stock Exchange, raising an additional $13 billion and broadening its investor base among Asian institutional and retail investors, reducing dependence on US capital markets.

22. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

23. 2021Alibaba

    Record Antitrust Fine

    Chinese regulators impose a 18.23 billion yuan ($2.8 billion USD) antitrust fine on Alibaba following a months-long investigation into its 'choose one from two' exclusivity practices at the time, the largest antitrust fine in Chinese regulatory history.

24. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

25. 2023Alibaba

    Six-Business-Unit Restructuring Announced

    Alibaba announces its most significant organizational restructuring, dividing the company into six independent business units each with its own CEO and board: Taobao Tmall Group, Cloud Intelligence Group, Alibaba International Digital Commerce Group, Cainiao S…

26. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

27. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

28. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

29. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

30. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

31. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

32. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

33. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

34. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about Alibaba vs AstraZeneca